Combining arsenic trioxide (ATO) with all-trans retinoic acid (ATRA) resulted into proteasome-dependent degradation of NPM1 oncoprotein and death in AML cell lines and primary AML cells carrying NPM1 mutations [43, 45]. The gene discussed is NPM1; the disease is acute myeloid leukemia.